53.36MMarket Cap-0.63P/E (TTM)
0.823High0.753Low170.78KVolume0.780Open0.792Pre Close135.85KTurnover0.61%Turnover RatioLossP/E (Static)65.88MShares2.09852wk High0.74P/B22.55MFloat Cap0.66052wk Low--Dividend TTM27.84MShs Float17.880Historical High--Div YieldTTM8.80%Amplitude0.660Historical Low0.795Avg Price1Lot Size
IO Biotech Stock Forum
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
IO Biotech announced promising Phase 2 results for its cancer vaccine IO102-IO103 combined with KEYTRUDA® in first-line metastatic lung cancer treatment. The study showed a 55% unconfirmed/48% confirmed overall response rate and 8...
loading...
No comment yet